Skip to main content
PATIENT SUPPORT SERVICES

Alongside™ KESIMPTA® for your patients

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections including serious bacterial, fungal, and new or reactivated viral infections; some have been fatal in patients treated with other anti-CD20 antibodies...

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
CoverMyMeds is a registered trademark of CoverMyMeds, LLC.
References: 1. Data on file. Market access. Novartis Pharmaceuticals Corp; East Hanover, NJ. September 2021. 2. Data on File. Unrestricted Commercial Market Access. Novartis Pharmaceutical Corp; East Hanover, NJ. October 2023. 3. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2023. 4. Data on file. Patient market research survey. Novartis Pharmaceuticals Corp; East Hanover, NJ. September 2021.